Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC IN RESPECT OF THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated May 12, 2025 (the "**Announcement**") in relation to the proposed implementation of the H share full circulation by the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company has recently submitted the filing with the CSRC in relation to H Share Full Circulation (the "**CSRC Filing**"). The Company has made filing application to the CSRC for the conversion of a total of 68,010,299 domestic shares and unlisted foreign shares of the Company into H Shares and the listing thereof on the Stock Exchange (the "**Conversion and Listing**"). The Board is pleased to announce that the Company has received a filing notice dated January 13, 2026 (the "**Filing Notice**") in respect of the Conversion and Listing. According to the Filing Notice, the CSRC Filing in relation to the Conversion and Listing has been completed, and if the Company wishes to continue the Conversion and Listing after 12 months from the date of the issuance of the Filing Notice, an updated filing to the CSRC will be required.

As of the date of this announcement, details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, January 26, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.